Baseline features of patients with TTP
Patient no. . | Sex . | Age at inclusion, y . | Duration of TTP, y . | Total no. of TTP episodes (TTP episodes/y) . | Kidney/brain involvement . | Previous treatments . | Time since last immunosuppressive treatment, mo . |
|---|---|---|---|---|---|---|---|
| 1 | F | 21 | First episode | 1 | –/altered cse | Plasma, vincristine | 1 |
| 2 | F | 58 | First episode | 1 | –/TCA seizures | Plasma, vincristine | 1 |
| 3 | F | 42 | 2 | 3 (1.5) | –/TCA | Plasma, vincristine | 2 |
| 4 | F | 21 | 2 | 3 (1.5) | –/– | Plasma, splenectomy | – |
| 5 | M | 36 | 5 | 12 (2.4) | SCr 150/TCA | Plasma, vincristine, IV Ig, splenectomy | 24 |
| 6 | M | 40 | 1 | 2 (2) | SCr 330/– | Plasma, rituximab | 10 |
| 7 | M | 31 | 4 | 4 (1) | SCr 710/– | Plasma, vincristine | 1 |
| 8 | M | 40 | 11 | 4 (0.4) | SCr 200/altered cse | Plasma, splenectomy | – |
| 9 | F | 40 | 7 | 4 (0.6) | –/altered cse | Plasma, vincristine, splenectomy | 48 |
| 10 | M | 60 | 12 | 11 (0.9) | SCr 880/TCA seizures | Plasma, vincristine, cyclosporine, intravenous Ig, splenectomy, rituximab | 17 |
| 11 | M | 40 | 28 | 15 (0.6) | SCr 180/TCA seizures | Plasma, vincristine, intravenous Ig, splenectomy, rituximab | 20 |
Patient no. . | Sex . | Age at inclusion, y . | Duration of TTP, y . | Total no. of TTP episodes (TTP episodes/y) . | Kidney/brain involvement . | Previous treatments . | Time since last immunosuppressive treatment, mo . |
|---|---|---|---|---|---|---|---|
| 1 | F | 21 | First episode | 1 | –/altered cse | Plasma, vincristine | 1 |
| 2 | F | 58 | First episode | 1 | –/TCA seizures | Plasma, vincristine | 1 |
| 3 | F | 42 | 2 | 3 (1.5) | –/TCA | Plasma, vincristine | 2 |
| 4 | F | 21 | 2 | 3 (1.5) | –/– | Plasma, splenectomy | – |
| 5 | M | 36 | 5 | 12 (2.4) | SCr 150/TCA | Plasma, vincristine, IV Ig, splenectomy | 24 |
| 6 | M | 40 | 1 | 2 (2) | SCr 330/– | Plasma, rituximab | 10 |
| 7 | M | 31 | 4 | 4 (1) | SCr 710/– | Plasma, vincristine | 1 |
| 8 | M | 40 | 11 | 4 (0.4) | SCr 200/altered cse | Plasma, splenectomy | – |
| 9 | F | 40 | 7 | 4 (0.6) | –/altered cse | Plasma, vincristine, splenectomy | 48 |
| 10 | M | 60 | 12 | 11 (0.9) | SCr 880/TCA seizures | Plasma, vincristine, cyclosporine, intravenous Ig, splenectomy, rituximab | 17 |
| 11 | M | 40 | 28 | 15 (0.6) | SCr 180/TCA seizures | Plasma, vincristine, intravenous Ig, splenectomy, rituximab | 20 |
Patients 1 to 6 were included during an acute episode of refractory TTP. Patients 7 to 11 were included during clinical remission. cse indicates consciousness; TCA, transient cerebrovascular attacks; SCr, maximal serum creatinine (μM); and –, absence.